BioNTech to Shut Three German Plants by 2028 as Founder Exit Talks Leave Patent Questions Unresolved
Published on 11/22/2026 at 16:10 | Editorial boerse-global.deBioNTech is preparing to wind down production at three German sites by the end of 2028, according to Handelsblatt, a retrenchment that lands alongside fresh questions about how the company will handle staff and intellectual property as its founders prepare to depart for a new venture.
The sites earmarked for closure are Marburg, Idar-Oberstein and Tübingen. Word of the manufacturing pullback emerged as Business Insider Deutschland reported that roughly 40 positions are set to go at BioNTech's main base in Mainz — a figure that sits on top of some 1,800 job cuts already mapped out at other locations. Handelsblatt has also reported site closures in Germany in connection with the savings programme.
Unsettled Ground at Arife
The cost drive coincides with uncertainty surrounding the planned move by founders U?ur ?ahin and Özlem Türeci to their new company, Arife. It remains unclear, Business Insider Deutschland reported, whether and how employees will transfer to Arife, and how rights to patents will be structured.
Should investors sell immediately? Or is it worth buying BioNTech?
Separately, BioNTech pushed back on the magazine's account of a voucher it has agreed to buy for accelerated review by the US Food and Drug Administration. Business Insider Deutschland had portrayed the voucher as tied to a specific product; the company said that is not the case and that it intends to deploy the voucher for a future marketing application covering one of its late-stage cancer drug candidates.
$205 Million for a Faster FDA Lane
The voucher itself comes from Scholar Rock, under a cash deal worth $205 million. Completion is subject to customary conditions, including antitrust clearance under the Hart-Scott-Rodino process.
On the analyst side, J.P. Morgan's Jessica Fye raised her price target on BioNTech on Thursday to $93 from $92 while keeping a "Neutral" rating on the stock.
Ad
BioNTech Stock: New Analysis - 22 November
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
